MSC therapy has been studied in renal insufficiency, chronic kidney disease (CKD), and lupus nephritis across multiple clinical contexts. A notable 2017 Annals of the Rheumatic Diseases randomised double-blind placebo-controlled trial examined allogeneic umbilical cord MSCs in lupus nephritis, with documented safety across long-term follow-up.
Kidney failure, whether from chronic kidney disease (CKD), diabetic nephropathy, lupus nephritis, or acute injury, is the progressive loss of the kidneys' ability to filter waste and regulate fluid balance. Dialysis substitutes the function mechanically. Transplant replaces the organ. Neither repairs what remains.
Kidney tissue has limited natural regenerative capacity. Once significant fibrosis develops, the decline is usually one-directional. MSC therapy is studied for anti-fibrotic, anti-inflammatory, and immunomodulatory effects that may slow this trajectory and support the remaining renal function.
Progressive loss of kidney function over months or years, most commonly driven by diabetes, hypertension, or glomerular disease. MSC therapy is studied for its potential to reduce inflammation, slow fibrosis, and protect remaining nephron function, particularly in earlier stages before dialysis becomes necessary.
A serious complication of systemic lupus erythematosus where the immune system attacks the kidneys. A 2017 randomised placebo-controlled trial of umbilical cord MSC infusion in lupus nephritis is among the most cited studies in the field, documenting safety and potential renal benefit.
Kidney damage caused by years of uncontrolled diabetes, one of the leading causes of dialysis globally. MSC therapy is studied for its potential to reduce the chronic inflammation and vascular damage driving renal decline in diabetic patients.
A broader category including reduced kidney function from various causes. MSC therapy is on 23C's treatable conditions list as renal insufficiency, assessed case-by-case based on the underlying cause, current kidney function, and medical history.
Intravenous delivery of highly potent umbilical cord mesenchymal stem cells. Low immunogenicity and strong anti-fibrotic and immunomodulatory potential make Wharton's Jelly UC-MSCs well-suited for renal applications.
Kidney decline is largely driven by fibrotic scarring of the renal tissue. MSC therapy is studied specifically for anti-fibrotic effects, the ability to calm the fibroblast activity that converts functional kidney tissue into scar.
For lupus nephritis, immune recalibration is the primary target. For diabetic nephropathy, metabolic and inflammatory support. For CKD of other causes, focused inflammatory and fibrotic management. Each protocol addresses the disease underneath the kidney damage.
The following improvements have been reported by past patients. Results vary by individual, improvements cannot be guaranteed.
The earlier cell therapy is considered, the more remaining kidney function there is to protect. Share your nephrologist's reports, recent eGFR and creatinine results, urinalysis, and the underlying cause if known. Our medical team will assess whether cell therapy is appropriate for your stage.
Request a Case Review